^
Association details:
| Biomarker: | NT5E overexpression + PD-L1 expression |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug Class: | PD1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
OC-146 The immunosuppressive role of CD73 in head and neck cancer patients treated with immunotherapy
Published date:
02/08/2023
Excerpt:
Our findings suggest that higher expression levels of CD73 could predict resistance to immunotherapy in patients with CPS positive R/M HNSCC. The addition of this biomarker to the routine evaluation of CPS could help to select the patients primary resistant to anti-PD-1 immunotherapy.
